Aspira Women’s Health Expands Senior Leadership Team with the Addition of Sandra Milligan, M.D., J.D. as President - Seite 2

Dr. Milligan said, “I am excited to join a team dedicated to enhancing outcomes for the millions of women suffering from gynecologic disease. Advocating for improvements in women’s health has been important to me throughout my career, and I believe Aspira’s pipeline of advanced diagnostic tools for ovarian cancer and endometriosis address a real unmet need for healthcare providers seeking to elevate the standard of care for women facing these devastating diseases. I look forward to working with everyone - from the laboratory bench to the field sales team - to realize Aspira’s potential as a world-class diagnostic company.”

Dr. Milligan joins Aspira from her role as Executive Vice President, Research and Development at Organon where she founded the R&D organization and advanced near-and long-term strategies for pipeline growth and value creation. Prior to Organon, she served as Senior Vice President, Global Regulatory Affairs and Clinical Safety at Merck where she developed and implemented proactive, worldwide strategies across a broad spectrum of therapeutics to enable rapid registration and robust life-cycle enhancement. Prior to Merck, Dr. Milligan served in advancing leadership roles in Research and Development at both Genentech and Amgen. Dr. Milligan earned a Doctor of Medicine from the George Washington University School of Medicine as well as a Juris Doctor from Georgetown University Law Center. After serving as a General Medical Officer in the US Army Medical Corps, she began her corporate career as an attorney in healthcare and corporate law prior to joining the pharmaceutical industry. She currently serves on the board of Gossamer Bio, a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutics in respiratory disease. She formerly served as board chair of DIA, a global organization that mobilizes life sciences professionals across multiple disciplines involved in drug development to take a collaborative approach to solve common challenges.

Dr. Todd Pappas, Vice President of Research and Development, has assumed responsibilities for product development, replacing Dr. Jody Berry, who stepped down earlier this month. Dr. Pappas first joined Aspira in 2013 and has experience in R&D, commercial, and clinical operations at Aspira, Delphi, Inc., Reliant Immune Diagnostics, and Luminex Corporation. His work has been central to the successful development of the OvaSuite test portfolio. Dr. Pappas will continue to be responsible for all aspects of Aspira’s scientific and product development activities and its relationships with academic partners, including Dana Farber Cancer Institute. Dr. Pappas received his Ph.D. in Neuroscience from The University of Texas Medical Branch at Galveston, and an MS in Biology from California State University, Long Beach.